Rifamycin SV MMX for the treatment of traveler's diarrhea

被引：2

作者：

Lin, Shu-Wen ^{[1
,2
,3
]}

Lin, Chun-Jung ^{[1
,2
]}

Yang, Jyh-Chin ^{[4
]}

机构：

[1] Natl Taiwan Univ, Grad Inst Clin Pharm, Coll Med, Taipei, Taiwan

[2] Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei, Taiwan

[3] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan

[4] Natl Taiwan Univ, Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2017年 / 18卷 / 12期

关键词：

Infectious diarrhea; non-absorbable antibiotics; rifamycin SV MMX; traveler's diarrhea; ANION TRANSPORTING POLYPEPTIDES; ESCHERICHIA-COLI; DOUBLE-BLIND; GASTROINTESTINAL TRANSIT; INFECTIOUS DIARRHEA; YOUNG-CHILDREN; RIFAXIMIN; RELEASE; PLACEBO; LOPERAMIDE;

D O I：

10.1080/14656566.2017.1353079

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Rifamycin SV MMX (R), a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies.Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea.Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine's efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination.

引用

页码：1269 / 1277

页数：9

共 50 条

[1] Rifamycin SV MMX®: A Review in the Treatment of Traveller's Diarrhoea
Hoy, Sheridan M.
CLINICAL DRUG INVESTIGATION, 2019, 39 (07) : 691 - 697
[2] Correction to: Rifamycin SV MMX®: A Review in the Treatment of Traveller’s Diarrhoea
Sheridan M. Hoy
Clinical Drug Investigation, 2019, 39 : 699 - 699
[3] Rifamycin SV-MMX® for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria
Steffen, Robert
Jiang, Zhi-Dong
Garcia, Monica L. Gracias
Araujo, Prithi
Stiess, Michael
Nacak, Tanju
Greinwald, Roland
DuPont, Herbert L.
JOURNAL OF TRAVEL MEDICINE, 2018, 25
[4] Treatment of Traveler’s Diarrhea
Maria Paulke-Korinek
Herwig Kollaritsch
Current Treatment Options in Infectious Diseases, 2014, 6 (1) : 74 - 80
[5] Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?
Zhu, Meng
Wang, Zhangcheng
Tian, Xiangfeng
Zhang, Yongsheng
HEPATOLOGY COMMUNICATIONS, 2024, 8 (08)
[6] Treatment and prevention of traveler's diarrhea
不详
CANADIAN FAMILY PHYSICIAN, 2015, 61 (11) : 976 - 977
[7] Prevention and treatment of traveler's diarrhea
Juckett, G
AMERICAN FAMILY PHYSICIAN, 1999, 60 (01) : 119 - +
[8] Traveler's Diarrhea: Prevention and Treatment
Steffen, R.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E13 - E13
[9] Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply
Steffen, Robert
DuPont, Herbert L.
JOURNAL OF TRAVEL MEDICINE, 2019, 26 (03)
[10] In Vitro Activity and Single-Step Mutational Analysis of Rifamycin SV Tested against Enteropathogens Associated with Traveler's Diarrhea and Clostridium difficile
Farrell, David J.
Putnam, Shannon D.
Biedenbach, Douglas J.
Moro, Luigi
Bozzella, Roberta
Celasco, Giuseppe
Jones, Ronald N.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) : 992 - 996

← 1 2 3 4 5 →